Chongqing Porton Pharmaceutical Co., Ltd.

As a world leading pharmaceutical CDMO, Porton provides global partners with efficient, flexible and high-quality one-stop solutions from small molecular APIs development to commercial supply. To broaden our service to downstream and enhance end-to-end delivery capability, Porton Pharmaceutical Division is established this July, with R&D centers in Shanghai and Chongqing, GMP pilot plant and commercial manufacturing sites in Chongqing. We are committed to build a drug formulation development and manufacturing service platform with state of art facilities and experienced core team, together with Porton’s API supply strength, deliver an integrated service for our partners.
The business scope of Porton Pharmaceutical Division includes pre-formulation study, formulation process development, clinical supply and commercial drug product manufacturing, covering dosage forms from various oral solids to injections and high-end complex formulations. The first phase of R&D center will be put into use in the first quarter of 2020, and the multi-purpose formulation workshops designed based on FDA and EU standards are planned to be completed in 2021.
At present, we are recruiting talents from both China and overseas. We have an energetic team with spirit of innovation in Porton family and expect you to join us!


Chongqing Porton Pharmaceutical Co., Ltd. was established in 2019 and is a controlled subsidiary of the listed company Porton (stock code: 300363). The company is committed to building a leading formulation R&D and manufacturing service platform. It has established R&D centers in Shanghai and Chongqing, and a GMP pilot plant and commercial manufacturing base in Chongqing.
The parent company Porton was established in July 2005 and is a leading pharmaceutical R&D and manufacturing outsourcing organization (CDMO). For more than a decade, Porton has consistently served the innovative drug field, accumulating leading R&D technology platform capabilities, comprehensive quality management and EHS management systems, and continuously providing services to globally renowned pharmaceutical companies and drug R&D institutions such as Johnson & Johnson, Gilead, Pfizer, GlaxoSmithKline, Novartis, Roche, and Boehringer Ingelheim. The company has operating and branch offices in China (Chongqing, Chengdu, Shanghai, Jiangxi, Hong Kong), the United States, Belgium, Switzerland, and the United Kingdom, with over 1,800 employees worldwide.
The establishment of Porton Pharmaceutical will fully leverage Porton's upstream and downstream synergies, forming a combined force with the existing leading small molecule drug process R&D and production platform, to provide global pharmaceutical companies and drug R&D institutions with drug development CMC services, MAH contract manufacturing services, and end-to-end customized R&D and production services from APIs to formulations.
Porton Pharmaceutical is an actively innovative and vibrant team. We eagerly look forward to joining hands with aspiring individuals from both China and overseas to contribute to enhancing China's pharmaceutical capabilities and bring new drugs to more patients faster.

Company website: ********************/